Breaking Zelenskyy Seeks Trump’s Help With Musk for Starlink Use in Russia Turkish Man Arrested in UK on U.S. Charges Related to Hamas Funding Allegations FCC Chairman Defends Agency Actions Amidst ABC Dispute Big Ten Conference Counters ‘Top-Heavy’ Narrative with Championship Claims Migrant Influx Swells Spanish Enclave to Near-Capacity

Friday July 31, 2026

Reporter

Johnson & Johnson

2Articles Published

5Communities Covered

Published Articles

Press Release

Johnson & Johnson’s RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancer

Jul 30

Press Release

TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma

Jul 23